InnoBM Pharmaceuticals Secures Tens of Millions in Series A+ Financing to Accelerate Innovative Drug Pipeline Development Based on Biomaterials Platform

Suzhou Baimai Biomedical (hereinafter referred to as “Baimai Biomedical”) recently announced the successful completion of its A+ round financing, amounting to tens of millions of yuan. This round was exclusively led by OrbiMed Asia Partners. The funds raised will be used to advance clinical trials of novel drugs for tumor immunotherapy and to develop the company’s innovative drug pipeline based on its proprietary biomaterials technology platform. Notably, Baimai Biomedical had just completed its Series A financing, led by Linghang Xinjie, one month prior.

Established in 2019, Baimai Biomedical is an innovative drug R&D company dedicated to platforming biomaterial technologies. The company’s founder, Professor Liu Zhuang, has been deeply engaged in the field of biomaterials for over a decade, focusing on frontier interdisciplinary research in biomaterials for tumor microenvironment modulation and biomaterials for delivery across macroscopic biological barriers. He has published numerous high-impact technical papers and holds independent intellectual property rights. Addressing unmet clinical needs, Baimai Biomedical leverages a unique “Vision” for new drug development, achieves original “Innovation,” and ultimately drives the “Translation” of biomaterials into innovative therapeutics.

Professor Liu Zhuang, founder of Baimai Biomedical, stated: “We appreciate the trust placed in us by Yuansheng Venture Capital. Leveraging our technology platform in the field of biomaterials, Baimai Biomedical is pursuing a novel approach to new drug development tailored to clinical needs. Meanwhile, we aim to explore a pathway aligned with China’s national context to efficiently drive the clinical translation of original laboratory research findings and fully realize their industrial value.”

Liu ZhuangProfessor at Soochow University

● Received a Bachelor’s degree from Peking University in 2004;

● Earned a Ph.D. from Stanford University in the United States in 2008, studying under renowned Chinese-American scientist Academician Hongjie Dai;

● Joined the Institute of Functional Nano & Soft Materials (FUNSOM) at Soochow University in 2009.

Professor Liu Zhuang specializes in interdisciplinary research in the field of biomaterials. He has published more than 400 academic papers, with total citations exceeding 75,000 and an H-index of 147. Professor Liu is a recipient of the National Science Fund for Distinguished Young Scholars; he has been selected as a “Leading Talent” under the Organization Department of the CPC Central Committee’s Ten Thousand Talents Program, appointed as a Chang Jiang Scholar Distinguished Professor by the Ministry of Education, and elected as a Fellow of the Royal Society of Chemistry (RSC Fellow) and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE Fellow). His academic honors include the Science Exploration Award, the First Prize of Jiangsu Provincial Science and Technology Awards (as the primary contributor), the Biomaterials Science Lectureship, and the China Youth Science and Technology Award. Since 2015, he has been consecutively listed among Clarivate Analytics’ “Highly Cited Researchers.” He serves as Associate Editor of Biomaterials, a flagship journal in the field of biomaterials. In 2019, he founded Suzhou Baimai Biomedical Co., Ltd., actively promoting the application and commercialization of independent innovative achievements.

Mr. Cheng Gang, Partner at Yuansheng Venture Capital, stated, “Professor Liu Zhuang has dedicated many years to the interdisciplinary fields of chemistry, materials science, biology, and medicine, achieving world-class results in fundamental mechanistic research. Furthermore, he has led the team at Suzhou Baimai Biomedical Co., Ltd. to develop highly innovative therapeutic products based on these findings, carving out a unique development path. In today’s era, which places significant emphasis on ‘independent innovation,’ such exploratory efforts hold particularly profound significance. We are delighted to have reached this collaboration with Baimai and look forward to providing sustained support for its future development.”

Securing consecutive rounds of financing within two months is a strong testament to the capital market’s high recognition of Suzhou Baimai Biomedical Co., Ltd.’s achievements over its three-year history and its future prospects. Leveraging recent funding and this latest round, Baimai Biomedical will continue to focus on new drug development based on biomaterial technology, drive efficient innovation through its platform-based technologies, establish a strategic presence in emerging industry sectors, and remain committed to building itself as a biotech company powered by intrinsic innovation.

YuanSheng Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 140 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, and healthcare services. The firm has achieved substantial investment returns, with 16 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanSheng Venture Capital has been repeatedly ranked among the Top 10 venture capital funds in China’s healthcare sector and recognized as one of the most active healthcare investment institutions in China. Bringing together seasoned professional investors and a world-class team of scientific advisors, YuanSheng Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, the firm is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Suzhou Baimai Biomedical Co., Ltd. was established in 2019. Leveraging the founder’s over a decade of interdisciplinary basic research experience in the field of biomaterials and grounded in robust scientific logic, the company has pioneered a unique approach that combines tumor microenvironment modulation with controlled drug release design to synergistically activate tumor-specific immune responses. By systematically addressing various bottlenecks in immunotherapy, the company aims to enhance the efficacy and clinical response rates of cancer immunotherapies, with multiple pipeline candidates expected to hold broad market prospects. Furthermore, utilizing biomaterials capable of crossing major biological barriers, the company is also developing novel delivery technologies for macromolecular drugs to improve patient adherence.